The Value of a New Cancer Biomarker fHER-2 Proto-oncogene in the Diagnosis of Feline Mammary Carcinoma

Maria Soares, Jorge Correia, José Cabeçadas, Conceição Peleteiro, Fernando Ferreira

Abstract

The overexpression of the Human Epidermal growth factor Receptor-2 (HER-2) oncogene in human breast cancer is associated with a poor prognosis and a specific treatment. Because of its importance and as a first line option for diagnosis, well established guidelines for its detection are based in immunohistochemical techniques, Still, in Veterinary Medicine there is little and inconsistent information about this subject. The aim of our study was to achieve an optimal immunohistochemical protocol for detection of fHER-2 in Feline Mammary Carcinoma (FMC). Five commercial anti-HER-2 antibodies were tested using three different protocols. The fHER-2 protein overexpression was detected in 10 of the 30 FMC cases (33.3%), when the optimized protocol was performed (associating the A0485 antibody with a longer antigen retrieval method). These results suggest that fHER-2 may play an important role in Feline Oncology and that the Cat can be a suitable animal model for human breast cancer research.

References

  1. De Maria R., Olivero M., Iussich S., Nakaichi M., Murata T. Bartolomeo B. and Di Renzo M.F.. (2005). Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Research, 65, 907-912.
  2. Gancberg D., Järvinen T., Leo A., Rouas G., Cardoso F., Paesmans M., Verhest A., Piccart M., Isola J. and Larsimont D. (2002). Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry. Breast Cancer Research and Treatment, 74, 113- 120.
  3. Martin de las Mulas, J., Van Niel M., Millán, Y., Blankenstein M.A., Van Mil F. and Misdorp W. (2000). Immunohistochemical analysis of estrogen receptors in feline mammary gland benign and malignant lesions: comparison with biochemical assay. Domestic Animal Endocrinology, 18, 111-125
  4. Martin de las Mulas, J., Van Niel M., Millán, Y., Ordás J., Blankenstein M.A., Van Mil F. and Misdorp W. (2002). Progesterone receptors in normal, dysplastic andtumourous feline mammary glands. Research in Veterinary Science, 72, 153-161.
  5. Ménard S., Tagliabue E., Campiglio M. and Pupa S.M. (2000). Role of HER2 Gene Overexpression in Breast Carcinoma. Journal of Cellular Physiology, 182, 150-162.
  6. Millanta F., Calandrella M., Citi S., Della Santa D. and Poli A. (2005). Overexpression of HER-2 in feline invasive mammary carcinomas. Veterinary Pathology, 42, 30-34.
  7. Misdorp W., Else R.W., Hellmen E. and Lipscomb T.P. (1999). Histologic Classification of Mammary Tumors of the Dog and the Cat. Armed Force Institute of Pathology and World Health Organization. Washington, DC.
  8. Ordás J., Millán Y., Dios R., Reymundo C. and de Las Mulas J.M. (2007). Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands. BMC Cancer, 7(179).
  9. Press M., Slamon D., Flom K., Park J., Zhou J. and Bernstein L. (2002). Evaluation of HER-2/neu Gene Amplification and Overexpression. Journal of Clinical Oncology, 20, 3095-3105.
  10. Rasotto R., Caliari D., Castagnaro M., Zanetti R. and Zappulli V. (2011). An Immunohistochemical Study of HER-2 Expression in FMC. Journal Comparative Pathology, 144, 170-179.
  11. Sáez A., Andreu F.J., Seguí M.A., Baré M.L., Fernández S., Dinarés C. and Rey M. (2006). HER-2 gene amplification by CISH compared FISH. The Breast, 15, 519-527.
  12. Stebbing J., Copson E. and O'Reilly S. (2000). Herceptin (trastuzamab) in advanced breast cancer. Cancer Treatment Reviews, 26, 287-290.
  13. Thomson T., Hayes M., Spinelli J., Hilland E., Sawrenko C., Phillips D., Dupuis B. and Parker R. (2001). HER-2/neu in Breast Cancer. Modern Pathology, 14 (11), 1079-1086.
  14. Winston J., Craft D.M., Scase T.J. and Bergman P.J. (2005). Immunohistochemical detection of HER-2/neu expression in spontaneous feline mammary tumours. Veterinary and Comparative Oncology, 3, 8-15.
  15. Withrow, S. J. and Vail, D. M. (2007). Withrow & MacEwen's Small Animal Clinical Oncology. (4th Ed.). Saunders, Philadelphia: Elsevier Inc.
  16. Wolff A.C., Hammond E.H., Schwartz J.N., Hagerty K.L., Allred D.C., et al. (2007). ASCO/CAP guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of Clinical Oncology, 25(1), 118-45.
Download


Paper Citation


in Harvard Style

Soares M., Correia J., Cabeçadas J., Peleteiro C. and Ferreira F. (2012). The Value of a New Cancer Biomarker fHER-2 Proto-oncogene in the Diagnosis of Feline Mammary Carcinoma . In Proceedings of the International Workshop on Veterinary Biosignals and Biodevices - Volume 1: VBB, (BIOSTEC 2012) ISBN 978-989-8425-94-2, pages 9-17. DOI: 10.5220/0003879300090017


in Bibtex Style

@conference{vbb12,
author={Maria Soares and Jorge Correia and José Cabeçadas and Conceição Peleteiro and Fernando Ferreira},
title={The Value of a New Cancer Biomarker fHER-2 Proto-oncogene in the Diagnosis of Feline Mammary Carcinoma},
booktitle={Proceedings of the International Workshop on Veterinary Biosignals and Biodevices - Volume 1: VBB, (BIOSTEC 2012)},
year={2012},
pages={9-17},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0003879300090017},
isbn={978-989-8425-94-2},
}


in EndNote Style

TY - CONF
JO - Proceedings of the International Workshop on Veterinary Biosignals and Biodevices - Volume 1: VBB, (BIOSTEC 2012)
TI - The Value of a New Cancer Biomarker fHER-2 Proto-oncogene in the Diagnosis of Feline Mammary Carcinoma
SN - 978-989-8425-94-2
AU - Soares M.
AU - Correia J.
AU - Cabeçadas J.
AU - Peleteiro C.
AU - Ferreira F.
PY - 2012
SP - 9
EP - 17
DO - 10.5220/0003879300090017